Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IDE034 |
| Synonyms | |
| Therapy Description |
IDE034 is a bispecific antibody-drug conjugate (ADC) targeting PTK7 and CD276 (B7-H3), which potentially induces cell cycle arrest, apoptosis, and tumor regression (Cancer Res (2026) 86 (7_Supplement): 232). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IDE034 | IDE-034|IDE 034 | CD276 Antibody 23 PTK7 Antibody 7 | IDE034 is a bispecific antibody-drug conjugate (ADC) targeting PTK7 and CD276 (B7-H3), which potentially induces cell cycle arrest, apoptosis, and tumor regression (Cancer Res (2026) 86 (7_Supplement): 232). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07503808 | Phase I | IDE034 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | Recruiting | USA | 0 |